We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

PepGen Inc (PEPG) USD0.0001

Sell:$4.15 Buy:$4.27 Change: $0.16 (3.97%)
NASDAQ:0.00%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$4.15
Buy:$4.27
Change: $0.16 (3.97%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$4.15
Buy:$4.27
Change: $0.16 (3.97%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

PepGen Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. Its proprietary enhanced delivery oligonucleotide (EDO), platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates that are designed to target the root cause of serious diseases. The Company’s pipeline consists of two clinical stage programs: PGN-EDO51 for duchenne muscular dystrophy (DMD) patients who are amenable to exon 51-skipping and PGN-EDODM1 for myotonic dystrophy type 1 (DM1) patients. It also has three additional preclinical stage programs: PGN-EDO53, PGN-EDO45 and PGN-EDO44.

Contact details

Address:
245 Main St, 2nd Floor
CAMBRIDGE
02142
United States
Telephone:
+1 (703) 4568000
Website:
https://pepgen.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PEPG
ISIN:
US7133171055
Market cap:
$131.36 million
Shares in issue:
32.60 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • James Mcarthur
    President, Chief Executive Officer, Treasurer, Secretary, Director
  • Noel Donnelly
    Chief Financial Officer
  • Paul Streck
    Executive Vice President, Head of Research & Development (R&D)
  • Dave Borah
    Senior Vice President - Investor Relations and Corporate Communications
  • Steve Han
    Senior Vice President - Clinical Development
  • Afsaneh Mohebbi
    Senior Vice President - Portfolio and Program Management
  • Hayley Parker
    Senior Vice President - Global Regulatory Affairs
  • Niels Svenstrup
    Senior Vice President - Chemistry, Manufacturing and Control
  • Mary Delena
    General Counsel, Company Secretary
  • Michelle Mellion
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.